Menu Search
Equities

Calliditas Therapeutics AB

CALTX:STO

Calliditas Therapeutics AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)206.20
  • Today's Change0.000 / 0.00%
  • Shares traded37.52k
  • 1 Year change+128.48%
  • Beta1.2676
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Calliditas Therapeutics AB had net income fall 13.08% from a loss of 412.27m to a larger loss of 466.19m despite a 50.32% increase in revenues from 802.88m to 1.21bn. An increase in the cost of goods sold as a percentage of sales from 1.89% to 5.01% was a component in the falling net income despite rising revenues.
Gross margin93.46%
Net profit margin-30.00%
Operating margin-22.05%
Return on assets-27.80%
Return on equity-157.20%
Return on investment-35.11%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Calliditas Therapeutics AB fell by 275.36m. Cash Flow from Financing totalled 199.65m or 16.54% of revenues. In addition the company used 434.66m for operations while cash used for investing totalled 13.75m.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.98
Tangible book value per share-6.76
More ▼

Balance sheet in SEKView more

Calliditas Therapeutics AB has a Debt to Total Capital ratio of 90.42%, a lower figure than the previous year's 154.56%.
Current ratio2.69
Quick ratio2.59
Total debt/total equity9.44
Total debt/total capital0.9042
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.